Aspire Biopharma Q3 2025 Earnings Report

Aspire Biopharma EPS Results

• Actual EPS: -$48.00
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Aspire Biopharma Revenue Results

• Actual Revenue: $0.00 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Aspire Biopharma Announcement Details

• Quarter: Q3 2025
• Date: 11/14/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Aspire Biopharma (NASDAQ:ASBP) Inc. is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.

The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis. In addition to epinephrine, Aspire has in-licensed a portfolio of novel PDE3/4 inhibitor compounds intended for maintenance therapy in chronic obstructive pulmonary disease (COPD) and severe asthma. Aspire’s development strategy emphasizes efficient clinical pathways and leveraging existing safety data to accelerate regulatory review.

Founded in 2007 and headquartered in Henderson, Nevada, Aspire Biopharma serves the U.S. market while exploring international licensing and distribution opportunities. The company maintains partnerships with contract development and manufacturing organizations (CDMOs) to support scalable production of its inhalation devices and formulations. Aspire’s leadership team combines expertise in pharmaceutical R&D, regulatory affairs, and pulmonary device engineering to drive its product pipeline toward late-stage clinical and market readiness.

Through strategic collaborations and targeted R&D investments, Aspire aims to address unmet medical needs in emergency medicine and chronic respiratory care. By focusing on inhaled delivery of both established and novel compounds, the company seeks to offer differentiated treatment options that improve patient outcomes and streamline acute care interventions.